MolecuLight develops a point-of-care fluorescence imaging device that detects elevated levels of bacteria in wounds, surgical sites, and other injuries. Its multi-modal tool combines bacterial detection, wound measurement, and imaging capabilities in a single device. The system integrates with electronic medical records, streamlines workflows, and improves documentation accuracy. By enabling clinicians to identify and quantify bacteria, MolecuLight aims to optimize treatment plans, accelerate healing, and reduce the risk of complications. The company is led by CEO Anil Amlani and recently completed a Series C financing to support wider patient access to its technology. MolecuLight commercializes a proprietary fluorescent imaging platform for real-time detection and localization of elevated bacterial loads in wounds. Its commercial products include the point-of-care handheld MolecuLight i:X and DX fluorescence imaging systems and associated accessories, which also provide digital wound measurement. The platform is being commercialized across multiple clinical markets. MolecuLight sells its devices in North America through a direct sales and clinical applications team and internationally via 15 specialized distributors across 18 countries. Led by CEO Anil Amlani, the company intends to use proceeds from a recent financing to support continued global expansion to meet customer demand for its devices. The financing amount was undisclosed in the article; no revenue or user metrics were provided.

Total raised

$12M

Funding rounds

2

Latest round

Series C

Latest activity

Aug 2024